Mount Sinai Tisch Cancer Center | Strategic Alliance Partners

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Ajai Chari, MD, discusses the impact of the COVID-19 outbreak on hospital protocols and the measures that are being taken to reduce the spread of the virus.

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

Joshua Brody, MD, discusses research with in-situ vaccination in non-Hodgkin lymphoma and strategies being developed to overcome acquired resistance.

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

William K. Oh, MD, discusses sequencing challenges in prostate cancer, biomarker development, and the impact of the PRINT trial.

John P. Sfakianos, MD, discusses some of the optimal and evolving management strategies in localized bladder cancer.

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

The International Association for the Study of Lung Cancer (IASLC) announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC CEO, Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology and Associate Director of Biomarker Discovery at The Tisch Cancer Institute at Mount Sinai and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.